Intravenous acyclovir in acute herpes zoster infection

In a double-blind, randomised trial, immune-competent adults with acute herpes zoster received either 5 mg/kg acyclovir (17) or placebo (20) intravenously three times daily. Acyclovir significantly improved rash development, as evidenced by reducing the time of new lesion formation and the times to...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infection Vol. 6; no. 2; pp. 157 - 161
Main Authors McGill, James, MacDonald, David R., Fall, Caroline, McKendrick, G. Donald W., Copplestone, Andrew
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.1983
Subjects
Acute Disease
Acyclovir - administration & dosage
Acyclovir - therapeutic use
Adult
Clinical Trials as Topic
Double-Blind Method
Female
Herpes Zoster - drug therapy
Humans
Male
Random Allocation
varicella-zoster virus
Online AccessGet full text

Cover

More Information
Summary:In a double-blind, randomised trial, immune-competent adults with acute herpes zoster received either 5 mg/kg acyclovir (17) or placebo (20) intravenously three times daily. Acyclovir significantly improved rash development, as evidenced by reducing the time of new lesion formation and the times to vesicle collapse and full crusting. Pain at the end of treatment and at three months was less in the treated group but the difference was not statistically significant. Ocular involvement was not affected.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-News-3
ISSN:0163-4453
1532-2742
DOI:10.1016/S0163-4453(83)92787-1